Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Moderate Buy” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $27.6667.

ELAN has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Leerink Partners upped their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Friday, March 27th. Barclays initiated coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th.

Elanco Animal Health Stock Up 0.1%

NYSE:ELAN opened at $23.11 on Friday. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $27.72. The stock’s fifty day simple moving average is $24.56 and its 200-day simple moving average is $22.82. The firm has a market capitalization of $11.49 billion, a P/E ratio of -48.14, a P/E/G ratio of 2.94 and a beta of 1.88.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the company posted $0.14 earnings per share. The firm’s revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC raised its position in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. SJS Investment Consulting Inc. lifted its holdings in shares of Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares in the last quarter. Huntington National Bank grew its position in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after purchasing an additional 1,087 shares during the period. Root Financial Partners LLC increased its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Finally, Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the 4th quarter worth approximately $41,000. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.